Navigation Links
Novel therapeutic target identified to decrease triglycerides and increase 'good' cholesterol
Date:10/20/2011

Researchers at NYU Langone Medical Center today announce findings published in the October 20 issue of Nature that show for the first time the inhibition of both microRNA-33a and microRNA-33b (miR-33a/b) with chemically modified anti-miR oligonucleotides markedly suppress triglyceride levels and cause a sustained increase in high density lipoprotein cholesterol (HDL-C) "good" cholesterol.

"The discovery of microRNAs in the last decade has opened new insights for up new avenues for the development of therapies targeted at these potent regulators of gene pathways," said lead author Kathryn Moore, PhD, associate professor in the Department of Medicine, The Leon H. Charney Division of Cardiology and The Marc and Ruti Bell Vascular Biology and Disease Program at NYU Langone Medical Center. "The current study is the first to show that inhibition of miR-33a, as well as miR-33b which is only found in larger mammals can suppress plasma triglyceride levels and increase circulating levels of HDL-C. This study highlights the benefits of modulating miR-33a/b and its downstream metabolic pathways for the treatment of conditions that increase cardiovascular disease risks, such as dyslipidemias and metabolic syndrome."

Metabolic syndrome is a combination of medical disorders that increase the risk of developing cardiovascular disease and diabetes. Cholesterol is a growing public concern worldwide characterized by an increase in triglycerides, decrease in plasma HDL-C, obesity and resistance to insulin that can lead to both cardiovascular disease and diabetes.

Recent studies have indicated miR-33a/b regulate genes involved in cholesterol and fatty acid metabolism pathways. miR-33a/b strongly represses the cholesterol transporter ABCA1, resulting in decreased generation of HDL-C and reverse cholesterol transport. In addition, miR-33a/b also inhibit key genes involved in fatty acid metabolism resulting in the accumulation of triglycerides. The ability to inhibit miR-33a/b to reverse these events provides a novel therapeutic approach to correct dyslipidemia and metabolic syndrome.

"This study represents a significant advance from our proof-of-concept studies in mice showing that anti-miR-33 can both raise HDL and improve existing atherosclerotic vascular disease," said Katey Rayner, PhD in the Department of Medicine at NYU Langone Medical Center and co-author of the study. "These exciting results now bring the use of miR-33 inhibitors one step closer to the clinic."


'/>"/>

Contact: Christopher Rucas
news@nyumc.org
212-404-3753
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related medicine news :

1. Innovation at Regenstrief: Leveraging novel ideas to improve health care
2. Novel technique reveals both gene number and protein expression simultaneously
3. Novel research set to pinpoint risk of heart attacks and strokes
4. Novel cytokine protects mice from colitis
5. FDA Approves Novel Melanoma Drug
6. St. Michaels North America first to use novel blood-cleaning procedure for kidney transplant
7. Novel DNA sequencer for MDCs systems biology
8. Novel Virus Jumped From Monkeys to Humans, Researchers Find
9. Novel combined therapy extends life, diminishes pain in brain cancer patients
10. Experiment aboard shuttle Atlantis will test novel therapy to build bone during space travel
11. Study uncovers novel genetic variation linked to increased risk of sudden cardiac arrest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... American Gene Technologies ... to its board of directors. Otterstatter is co-founder, president and CEO of ... technological innovations that lead to broad-based healthcare solutions. , “Jon knows how to ...
(Date:5/24/2016)... ... 24, 2016 , ... WaterAid launched the #perioddrama campaign to mark Menstrual Hygiene Day ... women around the world who do not have access to a toilet, even when they’re ... their dread of #perioddrama. The (sometimes hilarious) results help shine a light on the awkwardness ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... patient Services To Begin In June , Aloria Health, specializing in a re-imagined, ... opening of Aloria Milwaukee, its first treatment facility for outpatient, day treatment and ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... and tick-borne disease research and education, today announced that it has named Scott ... of the Bonnie J. Addario Lung Cancer Foundation (ALCF) in San Francisco, where ...
(Date:5/24/2016)... ... 24, 2016 , ... Dignity Health has announced it will be opening a ... licensed under Dignity Health Arizona General Hospital, which opened last year in the West ... that the new facility will complement Dignity Health’s existing hospitals’ emergency departments. “We ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 Open ... in Clinical Neurophysiology  Elsevier , a ... and services, today announced the launch of ... access journal that focuses on clinical practice issues in ... reports, clinical series, normal values and didactic reviews. It ...
(Date:5/23/2016)... PUNE, India , May 23, 2016 /PRNewswire/ ... research report "Patient Handling Equipment Market by Product ... Type of Care (Bariatric Care, Critical Care, Wound), ... Hospital) - Forecast to 2021", published by MarketsandMarkets, ... reach USD 17.18 Billion by 2021 at a ...
(Date:5/23/2016)... ALBANY, New York , May 23, 2016 /PRNewswire/ ... new market report titled, " Exocrine Pancreatic Insufficiency Market ... Forecast 2013 - 2023 ." According to the report, ... at a CAGR of 8.3% from 2015 to 2023 ... pancreatic insufficiency (EPI) is a condition characterized by the ...
Breaking Medicine Technology: